ITRM

Iterum Therapeutics plc ITRM

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.9M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-8.98M

Quarter to Sep 30

Free cash flow

$-7.46M

Quarter to Sep 30

Top Institutional Holders

as of Q2 2026
$542 total
BARCLAYS PLC
$539New
Cypress Capital Management LLC (WY)
$30.0%
See all 2 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q3 2025
EDGAR

EPS (Diluted)

Q3 2025
EDGAR

Free Cash Flow

Q3 2025
EDGAR

Debt/Equity

Q3 2025
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/ITRM

Earnings Per Share

13fpro.ai/company/ITRM

Loading ratio trend…

ITRM key financials by period

Reported revenue, net income and operating margin by fiscal year, from Iterum Therapeutics plc's annual filings on SEC EDGAR.

Iterum Therapeutics plc reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2019$37.0K$-103.1M—
FY 2018$869.0K$-77.1M—
FY 2017$508.0K$-29.4M—
Source: ITRM filings on SEC EDGAR →

About Iterum Therapeutics plc (ITRM): stock profile, AI score and financials

Iterum Therapeutics plc (ITRM) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. ITRM is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.9m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q3 2025), Iterum Therapeutics plc reports net income of $-9.0M, free cash flow of $-7.5M. ITRM trades on the Nasdaq exchange and files with the SEC under CIK 1659323. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ITRM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Iterum Therapeutics plc directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1659323 →